52-week mid-term efficacy of tildrakizumab in moderate-to-severe psoriasis: a real-life multicenter experience

Actas Dermosifiliogr. 2024 Mar 29:S0001-7310(24)00276-X. doi: 10.1016/j.ad.2023.08.019. Online ahead of print.ABSTRACTTildrakizumab is an IL-23-inhibitor that has been approved to treat plaque psoriasis. However, few reports have become available on its efficacy profile in the real-world. Our objective was to study the mid-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis in the Spanish routine clinical practice setting. This was a retrospective multicenter study that included a total of 91 psoriatic patients on tildrakizumab. The mean Psoriasis Area and Severity Index (PASI) was 9.09 (SD, 5.30). The overall tildrakizumab survival rate was 93.47% for a mean treatment exposure of 30.18 weeks (SD, 16,57). No drug discontinuation was associated with drug tolerability, or adverse reactions. Absolute PASI ≤ 3 was reached by 91.3% and 96.5% of the patients on weeks 28 and 52, respectively. Response was not impacted by weight, age (> 65), metabolic syndrome, presence of arthritis, or previous number of biological therapies used. Based on our own experience tildrakizumab is an effective strategy to treat plaque psoriasis and difficult-to-treat-areas.PMID:38556201 | DOI:10.1016/j.ad.2023.08.019

Source: Actas Dermo-Sifiliograficas - March 31, 2024 Category: Dermatology Authors: F J Melgosa Ramos A Mateu Puchades J Mat áix Díaz L Schneller Pavelescu I Belinch ón Romero S Santos Alarc ón Source Type: research